On the evening of March 27, Huadong Medicine announced that its exclusively distributed product, recombinant botulinum toxin type A for injection (trade name: Retoxin®), has been approved for marketing by the National Medical Products Administration for the temporary improvement of moderate to severe frown lines caused by the activity of the corrugator supercilii and/or depressor supercilii muscles in adults aged 65 and under.
The announcement shows that Retoxin® was independently developed by Chongqing Yuyan Pharmaceutical and owns global intellectual property rights. Huadong Medicine owns the exclusive commercialization rights of this product in the field of medical aesthetic indications in mainland China, Hong Kong and Macau, as well as related priority acquisition rights and priority negotiation rights. In addition, the company holds 4.2787% of the equity of Chongqing Yuyan Pharmaceutical Co., Ltd. through its wholly-owned subsidiary Xinkeli Aesthetics (Hangzhou) Medical Technology Co., Ltd.
According to Frost & Sullivan data, the Chinese botulinum toxin market grew from RMB 1.9 billion in 2017 to RMB 4.6 billion in 2021, with a compound annual growth rate of 25.6%, and is expected to reach RMB 39 billion in 2030.
Currently, Huadong Medicine has built a dual-engine product matrix of "medical aesthetic injection + photoelectric energy source", covering regenerative, hyaluronic acid, botulinum toxin and other injectable products as well as a variety of photoelectric devices. The approval of Retoxin® will further improve its medical aesthetic product layout.

https://mp.weixin.qq.com/s/wCYV9XwVozdOar-CUg-yMg